NCT06732804View on ClinicalTrials.gov

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Healthy Male and Female Subjects
Interventions
BIOLOGICAL

AVT80

Single subcutaneous injection of AVT80 (108mg)

BIOLOGICAL

Geographical region 1 Entyvio

Single subcutaneous injection of Geographical region 1 Entyvio (108mg)

BIOLOGICAL

Geographical region 2 Entyvio

Single subcutaneous injection of Geographical region 2 Entyvio (108mg)

Trial Locations (3)

8011

NZCR, Christchurch

Unknown

Veritus Research Pty Ltd, Bayswater

Investigational Site 0002, Auckland

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY